822 results on '"Mir O."'
Search Results
152. Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)
153. Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO)
154. Predictive factors for toxicity and survival of second line sunitinib in advanced gastrointestinal stromal tumours (GIST)
155. A Secure User Anonymity and Authentication Scheme Using AVISPA for Telecare Medical Information Systems
156. 1658P - No benefit of preoperative chemotherapy for primary retroperitoneal sarcomas: Results from a single center propensity-matched analysis
157. 1653P - Management of locoregional recurrence after radical resection of a primary non-metastatic retroperitoneal soft tissue sarcoma: Results of a retrospective series in a tertiary care center
158. 1641P - Adriamycin and ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: Results of a retrospective single-center study on 34 patients
159. 1643P - Pazopanib in advanced or metastatic synovial sarcoma: The Gustave Roussy experience
160. 1623P - Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib
161. 1611PD - A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)
162. 1617P - Multicentric retrospective analysis of patients with KIT exon 9 mutated GIST
163. 1612PD - A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)
164. 1613PD - mTOR inhibitors in uterine and extra-uterine malignant PEComas: A multicenter international case series retrospective analysis
165. 1608PD - Can we cure patients with abdominal desmoplastic small round cell tumor? Results of a retrospective multicentric study on 100 patients
166. 1601O - Natural history of sarcomas and impact of reference centers in the nationwide NETSARC study on 35,784 patients (pts) from 2010 to 2017
167. Toward a new strategy in desmoid of the breast?
168. Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients
169. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting
170. 1503P - Benefit of the use of tyrosine kinase inhibitors (TKIs) in patients (pts) with METAstatic Soft Tissue SARComa (STS) in a Real-Life Setting: an ancillary analysis of the METASARC Study
171. 1482PD - Notch pathway inhibition with LY3039478 in soft tissue sarcoma (STS) and gastrointestinal stromal tumours (GIST)
172. 1487P - Natural history of alveolar soft part sarcoma (ASPS): Impact of brain metastases and role of anti-angiogenic therapies (AAT)
173. 1163P - Immunotherapy phase I trials in patients over 70 years with advanced solid tumours: The Gustave Roussy experience
174. 1629 - Prevention of chemotherapy-induced nausea and vomiting in patients receiving ifosfamide: High dose chemotherapy
175. Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery?
176. ASTER 70s UNICANCER phase III Trial: Can a genomic prognosticator help tailoring adjuvant systemic treatment for luminal breast carcinoma in elderly women?
177. A Randomized Multicentre Phase Ii Study of Pazopanib Plus Best Supportive Care (Bsc) Vs Bsc Alone in Metastatic Gastrointestinal Stromal Tumors (Gist) Resistant to Imatinib and Sunitinib
178. Benefit of Maintenance Therapy with Trabectedin (T) Beyond the 6 First Cycles: Results of a Prospective Randomized Phase Ii Trial Comparing Interruption Vs. Continuation of T in Patients (Pts) with Advanced Soft Tissue Sarcoma (Asts): an Update
179. Outcome of First-Line Treatment of Elderly Advanced Soft Tissue Sarcoma (Sts) Patients: a Pooled Analysis of Eleven Eortc Soft Tissue and Bone Sarcoma Group Trials
180. Hypertension, Proteinuria and Overall Survival in Elderly Cancer Patients Treated with Bevacizumab
181. 6LBA - Preliminary safety and activity in a first-in-human phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT and PDGFRα activation loop mutants in advanced gastrointestinal stromal tumor (GIST)
182. Low skeletal muscle is associated with toxicity in patients included in phase I trials
183. Abstract P3-15-06: Results of the MARS study on the management of antiangiogenics’ renovascular safety in breast cancer
184. 1405PD - Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO)
185. 1416P - Predictive factors for toxicity and survival of second line sunitinib in advanced gastrointestinal stromal tumours (GIST)
186. 1406P - Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS)
187. 1404PD - Regorafenib (R) versus placebo (P) in soft tissue sarcomas (STS): analysis of genetic prognostic and predictive factors
188. 1396O - Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS)
189. Breast cancer in pregnancy: recommendations of an international consensus meeting.
190. Advanced chondrosarcomas: role of chemotherapy and survival
191. The FROG observatory on the tolerance of chemotherapy in the elderly in real life
192. E-015 Differential expression of cytokines in Mesenchymal stem cells as a potential target for Endovascular stem cell therapy
193. Quels traitements anticancéreux pendant la grossesse ?
194. Blood pressure monitoring in patients receiving bevacizumab
195. Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
196. Abstract P5-17-04: Management of Antiangiogenics' Renovascular Safety in breast cancer. Subgroup and intermediate results of the MARS Study.
197. Essential digital health.
198. Grossesse après cancer du sein : mise à jour des connaissances en 2012
199. PP106-SUN RELATIONSHIP BETWEEN INTESTINAL FUNCTION AND EXPOSURE TO SORAFENIB IN ADULT CANCER PATIENTS
200. Relationship Between Intestinal Function and Exposure to Sorafenib and Sunitinib in Cancer Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.